Wootton, R. E., Jones, H. J., & Sallis, H. M. (2021). Mendelian randomisation for psychiatry: How does it work, and what can it tell us? *Molecular Psychiatry, (2021).* https://doi.org/10.1038/s41380-021-01173-3
Mendelian randomisation for psychiatry: how does it work, and what can it tell us?

Robyn E. Wootton 1,2,3 · Hannah J. Jones 1,2,4,5 · Hannah M. Sallis 1,2,5,6

Received: 6 January 2021 / Revised: 5 May 2021 / Accepted: 12 May 2021
© The Author(s) 2021. This article is published with open access

Abstract
The successful prevention of mental illness relies upon the identification of causal, modifiable risk factors. However, observational evidence exploring such risk factors often produces contradictory results and randomised control trials are often expensive, time-consuming or unethical to conduct. Mendelian randomisation (MR) is a complementary approach that uses naturally occurring genetic variation to identify possible causal effects between a risk factor and an outcome in a time-efficient and low-cost manner. MR utilises genetic variants as instrumental variables for the risk factor of interest. MR studies are becoming more frequent in the field of psychiatry, warranting a reflection upon both the possibilities and the pitfalls. In this Perspective, we consider several limitations of the MR method that are of particular relevance to psychiatry. We also present new MR methods that have exciting applications to questions of mental illness. While we believe that MR can make an important contribution to the field of psychiatry, we also wish to emphasise the importance of clear causal questions, thorough sensitivity analyses, and triangulation with other forms of evidence.

Why is causal inference important?
Psychiatric illness presents a worldwide public health problem, with one in four people experiencing a mental illness in their lifetime [1]. In order to reduce this global burden of mental illness, prevention is key. Currently, robust prevention strategies are limited and therefore, we need to identify new modifiable risk factors that can become successful interventions. A pre-requisite for an effective intervention is a causal relationship between the modified risk factor and the risk of mental illness [2]. Although it does not guarantee intervention success, establishing causality is an important first step.

Why is it difficult to draw causal inference?
Numerous studies have explored potential risk factors for mental illness, but there is consensus for relatively few [3]. In part, this is due to a lack of specific knowledge about the biological pathways underlying mental illness, compared to many physical health conditions (for example, Type 2 diabetes). Without such knowledge, causal inference can be limited, especially if evidence is contradictory. Findings from traditional observational epidemiological studies might be contradictory due to high heterogeneity in mental health presentations, or due to bias from reverse causation and residual confounding. To illustrate this point, let’s take the example of cigarette smoking and depression. Smoking prevalence is much higher amongst individuals with depression than the general population. This could be due to a true causal effect (smoking is a causal risk factor for depression), and/or reverse causation (depression causes individuals to smoke more) and/or confounding (smoking and depression share common risk factors).
The gold standard approach to determine causality would be to conduct a randomised control trial (RCT). However, for certain risk factors (e.g. smoking), it would be highly unethical to randomise individuals to undertake a behaviour we know has adverse physical health consequences. While RCTs for other potential risk factors (e.g. physical activity) might not be unethical, they remain (as with all RCTs) time-consuming and expensive to conduct.

What is Mendelian randomisation (MR), and can it fix this?

MR is an increasingly popular method, made possible by the wide-spread availability of genotype data. MR can help to identify possible causal risk factors worth prioritising for follow up in RCTs and intervention trials. MR uses genetic variants as proxies for levels of the exposure in an instrumental variable analysis. For example, through genome-wide association studies (GWASs), we might identify genetic variants that pre-dispose individuals to smoke more or fewer cigarettes. These genetic variants can be used as an instrument to test causal effects of the exposure (e.g. smoking) on an outcome (e.g. depression), given that certain assumptions are satisfied (discussed below) [4]. Genetic variants that alter our average lifetime levels of the exposure are randomised at conception and inherited independently of confounding lifestyle factors. This is akin to a natural experiment, and the genetic variants are less likely to be biased by confounding and reverse causation than observed exposures [5]. Therefore, MR analyses can provide causal estimates, as long as the underlying assumptions are satisfied [4].

Notes of caution when using MR for psychiatry

Although MR has many benefits (i.e. high speed and low cost if suitable genotype and phenotype data are available), there are assumptions and limitations to consider. The three core assumptions of MR are: (1) the relevance assumption—the genetic instrument must be robustly associated with the exposure, (2) the independence assumption—the genetic instrument must not be associated with confounders of the exposure-outcome relationship and (3) the exclusion-restriction assumption—the genetic instrument must only be associated with the outcome via the exposure. These assumptions must hold if we are to make valid causal inference. More detailed discussion of the assumptions is available elsewhere [6, 7].

Here, we focus on limitations and assumption violations that are of particular importance when testing the effect of risk factors on psychiatric phenotypes. The limits of MR for psychiatric outcomes are largely related to the risk factor you wish to investigate. Risk factors with genetic instruments of known biological function pose fewer problems than those with more complex genetic aetiologies. Therefore, to fully explore the limits of MR for psychiatry, we predominantly focus on these latter complex risk factors (which are often behavioural or lifestyle factors).

First, the most important limitation to consider when using psychiatric and behavioural phenotypes is pleiotropy. Pleiotropy occurs when one genetic variant has effects on multiple traits. If these pleiotropic variants affect the outcome through pathways other than via the exposure, then two of the core MR assumptions (independence and exclusion-restriction) could be violated [6, 7]. This will bias estimates by reintroducing confounding. The genetic architecture of psychiatric phenotypes and behavioural risk factors are highly polygenic and pleiotropic [8], and the biological function of their associated genetic variants is often unknown. Consequently, instead of being able to rule out pleiotropic pathways through functional biology, sensitivity analyses must be conducted that are more robust to pleiotropy (discussed in detail elsewhere [9]). The complexity of these phenotypes, and their genetic instruments, means we must be cautious in our interpretation of the results and rigorous in our sensitivity analyses.

Second, the relationships between mental illnesses and behavioural risk factors are plausibly bi-directional. For example, lack of sleep might cause poor mental health and simultaneously, poor mental health might prevent efficient sleep. Bi-directional causal effects present a vicious cycle, which might begin before the onset of diagnosable psychiatric illness. Therefore, understanding bi-directional effects between two traits is important for effective prevention, and should be formally tested using MR where possible. Unfortunately, the interpretation of bi-directional MR is not always straight forward [10]. For example, evidence of a bi-directional relationship could arise because: (1) bi-directional associations are truly causal, (2) genetic instruments for both traits capture an underlying shared risk factor, (3) shared genetic variants act independently on both traits (horizontal pleiotropy) or (4) there is confounding through linkage disequilibrium (LD) [11]. We caution that without understanding the biological function of genetic variants on the two traits of interest, we cannot conclude the presence or direction of a true causal effect. However, approaches including pleiotropy-robust sensitivity analyses [12], multi-variable MR (MVMR) [13], colocalization analyses [14], Steiger filtering [15], inspection of LD plots and recently developed methods such as Latent Heritable Confounder MR [16] can help towards ruling out the alternative explanations.

Third, psychiatric phenotypes are highly heterogeneous. For example, depression is a common psychiatric illness, with varied presentations, severity, symptom course and...
risk factors [17]. Heterogeneity can be a problem for both the exposure and the outcome in MR. As the exposure, genetic instruments for behavioural risk factors (such as smoking) might exert their influence through biological pathways (e.g. neurochemical response to nicotine) or, indirectly, through behavioural pathways (e.g. personality traits of impulsivity and risk taking). Identifying these different pathways could help to better inform intervention targets. Recent methods aimed at identifying sub-groups of instruments that may act through different causal mechanisms, such as the contamination mixture method [18], may prove to be useful when investigating such multifactorial phenotypes. However, we often do not know through which pathways our genetic instruments act and consequently, heterogeneity can be difficult to distinguish from pleiotropy. One way to distinguish the two is the MR Egger intercept test, which can help to quantify the extent the instruments affect the outcome through pleiotropic pathways other than through the exposure [12].

Heterogeneity in the outcome can be a problem because heterogeneous patient groups might require different intervention strategies. Heterogeneity in the outcome will also reduce precision of our causal estimates, making it harder to identify a true causal effect should one exist. Within the field of psychiatric genetics, attention is turning towards the importance of reducing heterogeneity in phenotypes for GWASs [19, 20], and focusing on more homogenous sub-groups will become increasingly possible as sample sizes grow. However, even if more homogenous GWAS were to become a reality, we must not forget that MR is just the first of many steps in developing successful prevention strategies.

Fourth, due to this heterogeneity and the complexity of psychiatric phenotypes, each risk factor alone might explain only a small amount of variance in risk. Consequently, exploring possible modifiable risk factors using MR requires large sample sizes to reach adequate power. When using underpowered GWASs to identify instruments, the criteria for selecting genetic variants are often relaxed, for example including genetic variants associated at $p < 5 \times 10^{-7}$ rather than at genome-wide significance [21]. Inclusion of variants that are not as robustly associated with the exposure can have the unintended consequence of introducing more pleiotropic pathways and weak instrument bias, while on the other hand, inclusion of more variants is beneficial for several of the more pleiotropy-robust methods and prevents undue weight being placed on individual SNPs that could in fact be pleiotropic. Further MR sensitivity methods can be employed to adjust for possible weak instrument bias, such as Robust Adjusted Profile Scores [22] or methods that do not require $p$ value thresholds to select SNPs for inclusion but use genome-wide summary data and statistically account for horizontal pleiotropy (e.g. Causal Analysis Using Summary Effect estimates [23]). Nevertheless, when genetic instruments are only weakly associated with the exposure, we must be cautious in our interpretation of null MR results—an absence of evidence is not evidence of absence—and subsequent MR studies with stronger instruments might reach contradictory findings. Furthermore, although well-powered GWASs are becoming more available, obtaining the required sample size has sometimes come at the cost of detailed measurement of psychiatric illness, and increased phenotype heterogeneity [19]. This has been shown to have a detrimental impact on the specificity of the genetic variants identified [19].

Finally, MR gives an overall causal estimate for a chosen risk factor on a psychiatric illness. Consequently, inferences are limited in their temporality, linearity, generalisability and specificity. Temporality is limited because MR gives estimates of lifetime risk, and hence is not sensitive to critical windows or acute reactions. Linearity is limited because conventional MR estimates linear effects, so might not work for risk factors where we expect a non-linear relationship (e.g. hours of sleep). Extensions of the MR method to account for non-linear effects must be used to detect such relationships [24]. Generalisability is limited because the samples used are often highly selected with the most at risk individuals being the least likely to take part [25]. An assumption of the popular two-sample MR approach is that the exposure and outcome samples are relatively homogenous [26], which can be problematic, when our mental illness data are taken from clinical patient samples and our risk factor data from selected cohort samples. Furthermore, the majority of genetic studies restrict to individuals of European Ancestry, further limiting generalisability of findings [27]. Last, specificity is limited due to the phenotype definitions used in GWASs. GWASs typically combine data from multiple studies and it is often not possible to be overly specific with the phenotype definition, limiting the inferences for interventions. For example, there are genetic variants associated with overall physical activity, but not genetic variants specific to strengthening activity versus cardiovascular activity. These more nuanced questions might be better answered through intervention trials subsequent to MR analyses or perhaps, better powered GWAS samples with deeper phenotyping which will allow us to extend MR to answer these more specific questions in the future.

**Future applications**

Whilst keeping in mind these limitations, methods development for MR continues to extend its potential applications. Here, we focus on three recent MR methods that could be applied to important research questions around psychiatry. First, as discussed, mental illness tends to have...
for example, smoking in lung cancer, but once diagnosed with lung cancer, smoking cessation is not an effective treatment. Standard MR methods are not suitable for addressing questions of progression because they can be biased by selecting on disease incidence [30]. Emerging methods allow the extension of MR to specifically focus on individuals with an existing psychiatric diagnosis, by adjusting for this index event bias [31, 32]. Such extensions could enable us to identify causal risk factors for relapse or factors that predict recovery amongst those with diagnosed mental illness.

**Conclusion**

We are optimistic about the contribution of MR to the prevention of mental illness. As more novel genetic instruments become available, we hope that MR can be used to better understand the mechanistic steps along the causal pathway. For example, genetic instruments for emotion recognition processes or serotonergic pathways could move us beyond health behaviours as risk factors, and lead to novel therapeutic targets. However, we hope that this Perspective has emphasised that there are limitations of the MR method and all analyses should be carefully considered and cautiously interpreted. MR studies are easy to conduct, but they are not easy to conduct well. Therefore, we urge for careful study planning, generating a clear hypothesis prior to analysis and conducting rigorous sensitivity analyses. We emphasise that MR is far from a silver bullet. The strongest evidence of a causal effect occurs when multiple methods (each with their own limitations) all reach the same conclusions [33]. Furthermore, MR findings will always require following up in intervention trials to ensure that they ultimately produce successful prevention strategies.

**Acknowledgements** We would like to thank Professor Simon Gilbody for encouraging us to create this piece and the members of the Mental Health MR group at the MRC Integrative Epidemiology Unit for their thoughtful contributions.

**Funding** This work was supported by the Medical Research Council and the University of Bristol (MC_UU_00011/1, MC_UU_00011/7). Rew is supported by a postdoctoral fellowship from the South-Eastern Regional Health Authority (2020024). HMS is supported by the European Research Council (Grant ref: 758813 MHINT), HJJ is supported by the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.

**Compliance with ethical standards**

**Conflict of interest** The authors declare no competing interests.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. World Health Organization. The World Health Report 2001: mental health: new understanding, new hope. France: World Health Organization; 2001.
2. Pingault J-B, Cecil C, Murray J, Munafo M, Viding E. Causal inference in psychopathology: using Mendelian randomisation to...
identify environmental risk factors for psychopathology. Psychopathol Rev. 2016;4:4–25.
3. Köhler CA, Evangelou E, Stubbs B, Solmi M, Veronese N, Bellasis L, et al. Mapping risk factors for depression across the lifespan: an umbrella review of evidence from meta-analyses and Mendelian randomization studies. J Psychiatr Res. 2018;103:189–207.
4. Davey Smith G, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1–22.
5. Davey Smith G, Lawlor DA, Harbord R, Timpson N, Day I, Ebrahim S. Clustered environments and randomized genes: a fundamental distinction between conventional and genetic epidemiology. PLoS Med. 2007;4:e352.
6. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23:R89–98.
7. Davies NM, Holmes MV, Smith GD. Reading Mendelian randomisation: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601. https://doi.org/10.1136/bmj.k601.
8. Brainstorm Consortium, Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, et al. Analysis of shared heritability in common disorders of the brain. Science. 2018;360:eaap8757.
9. Zheng J, Baird D, Borges M-C, Bowden J, Hemani G, Haycock P, et al. Recent developments in Mendelian randomization studies. Curr Epidemiol Rep. 2017;4:330–45.
10. Richmond RC, Davey Smith G. Commentary: orienting causal relationships between two phenotypes using bidirectional Mendelian randomization. Int J Epidemiol. 2019;48:907–11.
11. Jones HJ, Martin D, Lewis SJ, Smith GD, O’Donovan MC, Owen MJ, et al. A Mendelian randomization study of the causal association between anxiety phenotypes and schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2020;183:360–9.
12. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44:512–25.
13. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. Int J Epidemiol. 2019;48:713–27.
14. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10:e1004383.
15. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 2017;13:e1007081.
16. Darrous L, Mounier N, Kutalik Z. Simultaneous estimation of bidirectional causal effects and heritable confounding from GWAS summary statistics. medRxiv. 2020. https://doi.org/10.1101/2020.01.27.20018929.
17. Hoare E, Callaly E, Berk M. Can depression be prevented? If so, how? JAMA Psychiatry. 2020. https://doi.org/10.1001/jama psychiatry.2020.1273.
18. Burgess S, Foley CN, Allara E, Staley JR, Howson JMM. A robust and efficient method for Mendelian randomization with hundreds of genetic variants. Nat Commun. 2020;11:376.
19. Cai N, Revez J, Adams MJ, Andlauer TF, Breen G, Byrne EM, et al. Minimal phenotyping yields genome-wide association signals of low specificity for major depression. Nat Genet. 2020;52:437–47.
20. Peterson RE, Cai N, Dahl AW, Bigdeli TB, Edwards AC, Webb BT, et al. Molecular genetic analysis subdivided by adversity exposure suggests etiologic heterogeneity in major depression. Am J Psychiatry. 2018;175:545–54.
21. Choi KW, Stein MB, Nishimi KM, Ge T, Coleman JR, Chen C-Y, et al. An exposure-wide and Mendelian randomization approach to identifying modifiable factors for the prevention of depression. Am J Psychiatry. 2020;177:944–54.
22. Zhao Q, Wang J, Hemani G, Bowden J, Small DS. Statistical inference in two-sample summary-data Mendelian randomization using robust adjusted profile score. arXiv. 2018.
23. Morrison J, Knoblauch N, Marcus JH, Stephens M, He X. Mendelian randomization accounting for correlated and uncorrelated pleiotropic effects using genome-wide summary statistics. Nat Genet. 2020;52:740–7.
24. Staley JR, Burgess S. Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genet Epidemiol. 2017;41:341–52.
25. Munafò MR, Tilling K, Taylor AE, Evans DM, Davey Smith G. Collider scope: when selection bias can substantially influence observed associations. Int J Epidemiol. 2018;47:226–35.
26. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med. 2017;36:1783–802.
27. Mills MC, Rahal C. A scientometric review of genome-wide association studies. Commun Biol. 2019;2:1–11.
28. Rosoff DB, Smith GD, Lohoff FW. Prescription opioid use and 433 risk for major depressive disorder and anxiety and stress-related 434 disorders: a multivariable Mendelian randomization analysis. 435 JAMA Psychiatry. 2020.
29. Rees JMB, Foley CN, Burgess S. Factorial Mendelian randomization: using genetic variants to assess interactions. Int J Epidemiol. 2020;49:1147–58. https://doi.org/10.1093/ije/dyz161.
30. Paternoster L, Tilling K, Smith GD. Genetic epidemiology and Mendelian randomization for informing disease therapeutics: conceptual and methodological challenges. PLoS Genet. 2017;13: e1006494.
31. Dudbridge F, Allen RJ, Sheehan NA, Schmidt AF, Lee JC, Jenkins RG, et al. Adjustment for index event bias in genome-wide association studies of subsequent events. Nat Commun. 2019;10:1561.
32. Mahmoud O, Dudbridge F, Smith GD, Munafò M, Tilling K. Slope-Hunter: a robust method for index-event bias correction in genome-wide association studies of subsequent traits. bioRxiv. 2020. https://doi.org/10.1101/2020.01.31.928077.
33. Munafò MR, Davey Smith G. Robust research needs many lines of evidence. Nature. 2018. https://doi.org/10.1038/d41586-018-01023-3.